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AbstrAct:
Advanced gastrointestinal (GI) malignancies are varied in presentation, prognosis, 
and treatment options. With the exception of resectable recurrent colorectal cancer, 
metastatic GI malignancies are incurable.  Cytotoxic chemotherapies have been the 
mainstay of therapy for decades but limited extension of survival or clinical benefit 
has been achieved in non-colorectal GI cancers.  There has been great interest in the 
incorporation of antiangiogenic strategies to improve outcomes for these patients.  
Clear  benefits  have  been  identified  with  bevacizumab  and  sorafenib  in  colorectal  cancer 
and hepatocellular cancer, respectively; other GI tumor sites have lacked impressive 
results with antiangiogenic agents.  In this review, we will present the benefits, or 
lack thereof, of clinically tested antiangiogenic compounds in GI malignancies and 
explore some potential new therapeutic anti-angiogenesis options for these diseases.
INtrODUctION 
Up-regulation of angiogenesis is required 
for development of malignancy, tumor growth and 
progression [1,2].  The vascular endothelial growth factor 
family of ligands (VEGF-A (VEGF), VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, and placental growth factor(PlGF)) 
and receptors (VEGFR-1, VEGFR-2, VEGFR-3, FLT-3, 
platelet derived growth factor receptor (PDGFR), and 
C-KIT) are the most studied angiogenic pathways [3,4]. 
(FIGURE 1)  Extracellular interaction of the ligands 
with VEGFRs encourages receptor dimerization, leads to 
receptor autophosphorylation, and subsequently activates 
downstream angiogenic and growth pathways.  VEGF 
binds primarily to VEGFR-1 and VEGFR-2 whose 
expression is more pronounced in tumor vasculature 
endothelial cells [5].  VEGF/VEGFR binding results in 
cellular proliferation, vascular differentiation, altered 
vascular permeability, and migration [6-13].  
Inhibiting cellular angiogenic machinery is a 
well researched area of cancer care.  Over the last 
decade, several antiangiogenic compounds have been 
developed, investigated, and approved for cancer 
treatment.  Inhibiting angiogenesis can occur via various 
mechanisms.  To date, drug development has focused on 
blocking this pathway via inhibition of the ligand (VEGF), 
the receptors (VEGFRs), and the effector intracellular 
tyrosine kinase pathways. (TABLE 1)  When the addition 
of bevacizumab, a monoclonal antibody (mAb) inhibiting 
VEGF, to chemotherapy for advanced colorectal cancer 
(CRC)  offered  an  almost  5  month  survival  benefit, 
considerable effort was directed to develop other 
angiogenesis blockers[14].  Subsequent studies have 
attempted to match this benefit in other tumor types.  
Advanced gastrointestinal (GI) malignancies are 
a wide spectrum of diseases with variable prognoses 
depending on the stage at diagnosis.  On one end of this 
spectrum is advanced gastric and pancreatic cancers 
which have uniformly poor overall survival from 
diagnosis regardless of treatment; on the other end of 
this spectrum is metastatic CRC which, when treated 
with a sequence of well established therapies, affords 
a median survival in excess of two years.  The use of 
biologic agents, particularly antiangiogenics, has been at 
the forefront of clinical investigations in GI malignancies 
for most of the last decade.  Mechanistically, the theories 
behind inhibiting new blood vessel formation, including 
improved delivery of concurrently administered cytotoxic 
drugs and promotion of effective delivery of blood and 
nutrients intra-tumorally, are valid.  Unfortunately, for Oncotarget 2010; 1:  515 - 529 516 www.impactjournals.com/oncotarget
uncertain reasons, many antiangiogenic agents have not 
been effective in GI cancers.  Herein, we review the 
use of antiangiogenic compounds which have proven 
clinical benefit in GI malignancies, discuss some novel 
agents currently under investigation, and make critical 
conclusions as to the effectiveness of this avenue as anti-
cancer treatment in GI tumors
EsOPHAGOGAstrIc cANcErs (EGc)
Gastric and esophageal cancers are the second and 
sixth leading causes of cancer related death worldwide, 
respectively [15].  Esophageal adenocarcinoma is 
now more prevalent than squamous cell carcinoma in 
North America and Western Europe and, as it is often 
difficult  to  determine  if  the  cancer  originates  in  the 
gastroesophageal junction or distal esophagus, patients 
with advanced diseases are often treated akin to advanced 
gastric adenocarcinoma.  There is little data on the role 
of angiogenesis inhibitors in patients with esophageal 
squamous cell carcinoma.  As such, this discussion will be 
limited to EGC adenocarcinoma. 
Patients with metastatic EGC have 5 year survival 
rates of 10-15%.  When compared to best supportive 
care, palliative cytotoxic chemotherapy improves survival 
[16-18].  Although there is no single internationally 
accepted standard of care regimen, the best survival rates 
are achieved with three drug combinations compared to 
doublet therapy [19].
VEGF and angiogenesis appear to have an important 
role in pathogenesis and prognosis of EGC.  VEGF 
expression increases with increasing stage and disease 
burden in EGC [20,21].  Furthermore, VEGF expression 
is a negative prognostic factor for survival in this patient 
group [22,23].  In a gastric xenograft model, inhibition 
of VEGF activity by an immuno-neutralizing antibody 
was effective suggesting that VEGF inhibition may have 
therapeutic value [24].  Phase II studies of bevacizumab 
combined with chemotherapy (irinotecan and cisplatin; 
oxaliplatin and docetaxel or 5-fluoruracil (FU); docetaxel, 
cisplatin, and FU) showed promising results in previously 
treated and untreated patients (RR 63-71%) [25-28].  The 
phase III study, AVAGAST, which combined bevacizumab 
or placebo with capecitabine and cisplatin showed a 
significant improvement in overall response rate (ORR 
38% vs 29.5%) and progression free survival (PFS 6.7 vs 
5.3 months) [29].  However, the study failed to improve 
overall survival (OS), its primary endpoint.
Ramucirumab, a monoclonal antibody directed 
at VEGFR-2, is currently being tested in a randomized 
phase III study as a second-line agent in metastatic EGC 
(NCT009117384).
Several small molecule TKIs to VEGFRs have also 
undergone early phase II testing in EGC.  Sorafenib in 
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Figure 1:  Vascular endothelial growth factor pathway 
adapted from Qc previous paper. Abbreviations: VEGF, 
vascular endothelial growth factor; VEGFR, vascular endothelial 
growth factor; PDGF, platelet derived growth factor ; PDGFR, 
platelet derived growth factor receptor; PlGF, platelet derived 
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table 1.  comparison of current antiangiogenic agents being used or investigated in GI 
malignancies.
Anti-
angiogenic 
agent
Mechanism of 
Action
tumour sites 
of Interest
toxicities from dose finding studies
Bevacizumab IV recombinant 
humanized 
monoclonal antibody 
against VEGF
CRC Anemia, dyspnea, intracranial bleed, tumor 
hemorrhage
Sunitinib Oral multitargeted 
TKI inhibiting 
VEGFR-1, VEGFR-2, 
PDGFR-β, c-KIT, 
FLT3, and RET
HBC Fatigue, HTN, bullous skin toxicity, elevated 
lipase/amylase, decrease LVEF, edema, 
thrombocytopenia, tumor necrosis, asthenia, 
nausea, vomiting, HTN, PE, phlebitis, 
neutropenia, thrombocytopenia, skin toxicity, 
tumor related fistulas, anemia
Sorafenib   Oral multitargeted 
TKI inhibiting 
VEGFR-1, VEGFR-2, 
PDGFR-β, Raf-1, B-
Raf, and intracellular 
serine-threonine 
kinases
HBC Rash, HTN, dyspnea, fatigue, HFS, abdominal 
cramping, diarrhea, retrosternal pain, edema of 
uvula, anorexia, fatigue, anorexia, diarrhea, 
rash/desquamation, HFS, nausea, alopecia
Cediranib Oral TKI to VEGFR-
1, VEGFR-2, 
VEGFR-3
Gastric
CRC
Hypertension, hypertensive crisis, 
hypoglycemia, elevated bilirubin, fatigue, 
diarrhea, nausea, dysphonia, hypertension, 
vomiting, anorexia
Valatinib Oral TKI to VEGFR-
1, VEGFR-2, 
VEGFR-3, PDGFR, 
c-kit
CRC Lightheadedness, fatigue, vomiting, nausea, 
diarrhea, HTN
Brivanib Oral TKI to VEGFR-
2 and FGFR-1
CRC HTN, fatigue, AST/ALT elevation, thyroid 
dysfunction, hyponatremia
ZD6474 Oral TKI to VEGFR-
2, RET, Flt-4, 
VEGFR-3, EGFR
pancreas Diarrhea, HTN, rash, folliculitis, 
hypophosphatemia, increased ALT, bowel 
obstruction, colitis, fatigue, thrombocytopenia, 
rash, nausea, HTN, fatigue, anorexia, CHF, PE, 
DVT, bowel ischemia
ABT-869 Oral TKI to VEGFR-
1, VEGFR-2, 
VEGFR-3, PDGFRß, 
and Flt3
CRC
HCC
Fatigue, proteinuria, HTN, asthenia, HFS, 
myalgia
Ramucirumab IV anti-VEGFR2 
mAB
CRC HTN, DVT, headache, proteinuria, vomiting, 
amylasemia
IMC-18F1 IV anti-VEGFR1 
mAB
CRC Fatigue, nausea, anemia
Aflibercept VEGF-A, VEGF-B, 
PIGF fully human 
recombinant decoy 
fusion protein
gastric
pancreas 
CRC
Rectal ulceration, proteinuria, HTN
table 1:  comparison of anti-angiogenic agents. Abbreviations: VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial 
growth factor; PDGF, platelet derived growth factor ; PDGFR, platelet derived growth factor receptor; PlGF, platelet derived growth factor; 
CRC, colorectal cancer; HBC, hepatobiliary cancers; HTN, hypertension; DVT, deep venous thrombosis; CHF, congestive heart failure; PE, 
pulmonary embolism; ALT, alanine transferase; HFS, hand-foot syndrome; LVEF, left ventricular ejection fractionOncotarget 2010; 1:  515 - 529 518 www.impactjournals.com/oncotarget
combination with docetaxel and cisplatin in treatment-
naive patients with metastatic EGC demonstrated partial 
responses (PR) of 41%, median PFS of 5.8 months, and 
median OS of 13.6 months [30].  Sunitinib as a second-
line single agent treatment for advanced gastric cancer 
demonstrated a disease control rate of 35% [31].
cANcErs OF tHE HEPAtObILIArY 
trAct
Hepatocellular carcinoma (Hcc)
HCC is the third leading cause of death worldwide 
after lung and gastric cancer [32].  Less than 30% of 
patients are eligible for surgery due to advanced stage 
of disease at presentation and treatment with cytotoxic 
chemotherapy has been disappointing with multiple 
studies failing to show an improvement in OS [33].   
HCC’s are highly vascular tumors.  High microvessel 
density and levels of circulating VEGF are associated with 
poorer outcomes, thus making the angiogenesis pathway 
an attractive therapeutic target [34-39]. 
Sorafenib is the first systemic agent demonstrating an 
improvement in OS in patients with advanced HCC.  The 
initial phase II study of 137 patients showed promising 
activity with a median OS of 9.2 months and a median 
time to progression (TTP) of 5.5 months [40].  Patients 
with Child-Pugh Class B liver function had similar 
incidence of drug-related adverse events but had more 
frequent worsening of liver disease (encephalopathy 11% 
vs. 2%; worsening ascites 18% vs. 11%) than patients 
with Child-Pugh A liver function as well as significantly 
worse OS (14 weeks vs. 41 weeks) [41].  Two phase 
III, multicenter, randomized, placebo-controlled studies 
confirmed the activity of this agent.  Both studies limited 
enrollment to patients with Childs-Pugh A liver function. 
The SHARP study enrolled patients from Europe, North 
and South America and Australasia and had hepatitis C 
and alcohol as the predominant risk factors for HCC.  The 
Asia-Pacific  trial  enrolled  patients  from  China,  South 
Korea and Taiwan and had hepatitis B as the predominant 
HCC risk factor.  Both studies demonstrated a significant 
OS improvement (SHARP: 10.7 vs. 7.9 months, HR 
0.69, p<0.001; Asia-Pacific: 6.5 vs. 4.2 months, HR 0.68, 
p=0.014) and disease control rate (SHARP: 43% vs. 32%, 
p=0.0002; Asia-Pacific: 35.5% vs. 15.8%, p=0.0019) with 
sorafenib as compared to best supportive care.  Response 
rates (RR) were low (2% and 3.3% respectively) and 
there was no difference between the arms in time to 
symptomatic progression [42,43].
In early phase II studies, sunitinib also demonstrated 
activity in the treatment of advanced HCC [44,45].   
However, a phase III study comparing sunitinib to 
sorafenib was terminated in April 2010 due to increased 
toxicity in the sunitinib arm; it did not meet the pre-defined 
criteria for superiority or non-inferiority (NCT00699374).
Two phase II studies examining the activity of  single-
agent bevacizumab in advanced HCC both demonstrate 
promising antitumour activity (RR 12.5-13%; PFS 
6.9 months) but toxicity, in particular gastrointestinal 
bleeding, is concerning, [46,47].  There have been three 
single arm phase II studies of bevacizumab in combination 
with a variety of chemotherapy regimens which show 
evidence of clinical activity but randomized comparisons 
are required [48-50].
biliary tract cancers (btc)
BTC, which include intra- and extra-hepatic 
cholangiocarcinoma and gallbladder malignancies, are rare 
tumours accounting for only 3-4% of GI cancers.  Surgery 
is the only curative option but most patients present with 
unresectable disease [51].  In patients with advanced BTC, 
only recently has treatment with gemcitabine and cisplatin 
demonstrated an improvement in OS [52]. 
In contrast to HCC, BTC metastases tend to be 
hypovascular.  However, VEGF expression in these 
tumors does correlate with advanced disease stage and 
poor prognosis [53,54].  A phase II clinical trial using 
gemcitabine and oxaliplatin (GEMOX) combined with 
bevacizumab demonstrated modest activity with an ORR 
of 40%, median PFS 7.0 months and median OS of 12.7 
months [55].  However, the 6-month PFS did not meet 
the pre-specified endpoint of an improvement from 50% 
to 70% as compare to GEMOX alone.  Randomized 
comparisons are needed to evaluate the added benefit of 
bevacizumab.  To date, attempts at TKI inhibition have 
not been beneficial in BTC.  Two phase II clinical trials 
of  sorafenib  failed  to  show  significant  clinical  activity 
[56,57]. 
PANcrEAtIc ADENOcArcINOMA
Pancreas cancer is the fourth commonest cause of 
cancer-related mortality across the world, with incidence 
equaling mortality [58].  Only 15-20% of patients present 
with surgically resectable disease and, of these, only 
20% will survive 5 years.  The OS for patients with 
metastatic or locally advanced disease is 4-9 months.   
Gemcitabine remains the standard chemotherapy for this 
disease with a modest benefit in OS [59].  Multiple studies 
combining gemcitabine with other cytotoxic agents have 
not demonstrated improvement in survival [60-62].  The 
phase III randomized trial of gemcitabine vs gemcitabine 
+ erlotinib, an epidermal growth factor receptor (EGFR) 
inhibitor did improve median OS from 5.91 months to 
6.24 months but the clinical relevance of this benefit is 
questioned by the medical oncology community [63].  
VEGF and its receptors (VEGFR-1 and VEGFR-2) Oncotarget 2010; 1:  515 - 529 519 www.impactjournals.com/oncotarget
are co-expressed in pancreatic cancer suggesting that 
VEGF could have autocrine effects on pancreatic cancer 
cells that express VEGF receptors and paracrine effects 
on microvascular endothelial cells [64-66].  In animal 
models, VEGF TKIs and anti-VEGF and anti-VEGFR-2 
antibodies inhibit growth and angiogenesis associated 
with pancreatic tumors and potentiated the tumoricidal 
effect of gemcitabine [67-71].
Activity in the phase II trials combining gemcitabine 
and bevacizumab looked promising and, based upon 
these results, bevacizumab was tested in two randomized 
controlled phase III studies [72,73].  In these trials, 
gemcitabine with or without bevacizumab and gemcitabine 
plus erlotinib with or without bevacizumab both failed to 
show a survival benefit with the addition of bevacizumab 
[74,75].  Other VEGF targeted therapies tested in the 
setting of pancreatic cancer include sorafenib, axitinib, 
and sunitinib but limited activity in phase II trials ended 
further investigations into these agents [76-78]. 
cOLOrEctAL ADENOcArcINOMAs
Colorectal cancer is the fourth most common 
cancer in men and women [79].  Patients with untreated 
metastatic CRC (mCRC) have a median survival of 5 – 6 
months [80].  Prior to the emergence of the topoisomerase 
I inhibitor irinotecan in 1996, treatment for metastatic 
colorectal cancer was limited to FU and leucovorin 
(LV). This was followed in 2004, by the introduction 
of oxaliplatin.  An analysis of several large, phase III 
studies demonstrates that exposure at some time during 
treatment to these three agents (FU plus LV, irinotecan, 
and  oxaliplatin)  significantly  improves  overall  survival 
OS of mCRC to an average of 20 months [81]. 
In early pre-clinical work on colon cancer 
specimens, a correlation was noted between increased 
VEGF expression and proliferative activity in tumors 
[82].  Furthermore, in vivo murine antihuman monoclonal 
antibodies targeted against VEGF inhibited growth of 
human tumor xenografts [83].  Based on these findings, 
two randomized phase II studies combining FU +LV 
with bevacizumab demonstrated improved clinical 
efficacy  over  FU  +  LV  alone  [84,85].  (Table  2)  The 
landmark phase III trial by Hurwitz et al which led to 
the clinical approval of bevacizumab for the treatment 
of mCRC compared either FU + LV + irinotecan (IFL) + 
bevacizumab to IFL + placebo which reported a median 
OS of 20.3 months versus 15.6 months [14]. (Table 2)   
However, the IFL regimen has fallen out of favor due 
to the improved tolerance and efficacy of infusional FU 
+  irinotecan  (FOLFIRI)  as  compared  to  modified  IFL 
(mIFL) [86].  This trial was then modified in April 2004 to 
assess the addition of bevacizumab to both of these arms 
of the trial with both the PFS and median OS favoring the 
patients receiving FOLFIRI + bevacizumab as compared 
to mIFL + bevacizumab.  Although this trial did not 
directly compare FOLFIRI administered with or without 
bevacizumab, it does suggest FOLFIRI + bevacizumab is 
more efficacious than mIFL + bevacizumab.
The combination of bevacizumab with oxaliplatin-
based chemotherapy as first line therapy has also been 
investigated in a randomized, double-blind study 
designated N016966 [87].  In this study, 1,400 patients 
received FU + oxaliplatin (FOLFOX) or capecitabine 
+ oxaliplatin (XELOX), with either bevacizumab or 
placebo.  Although an improvement in median PFS was 
seen, neither an improvement in RR or median OS was 
achieved. (Table 2)  It is hypothesized that the failure to 
improve median OS was due to early discontinuation of 
the capecitabine or FU and bevacizumab when oxaliplatin 
peripheral neurotoxicity occurred hence diminishing the 
impact of bevacizumab [88].  In the second-line setting, 
table 2.  Seminal publications supporting the use of bevacizumab in advanced colorectal cancer
First-Line Phase II trials relevant treatment Arms n response rate Progression-Free 
survival
Overall survival
AVF0780g
Roswell Park 36 17%
Not 
applicable
5.2 months
Not 
applicable
13.8 months
Not 
applicable Roswell Park + Bevacizumab 5 mg/kg 35 40% 9.0 months 21.5 months
Roswell Park + Bevacizumab 10 mg/kg 33 24% 7.2 months 16.1 months
AVF2192g
Roswell Park + Placebo 105 15.2% Not 
applicable
5.5 months Not 
applicable
12.9 months Not 
applicable Roswell Park + Bevacizumab 104 26.0% 9.2 months 16.6 months
First-Line Phase III 
trials
relevant treatment Arms n response rate Progression-Free 
survival
Overall survival
AVF2107g
IFL 411 34.8%
p = 0.004
6.2 months HR 0.54
p < 0.001
15.6 months HR 0.66
p < 0.001 IFL + B 402 44.8% 10.6 months 20.3 months
BICC-C
FOLFIRI 144 47.2% 7.6 months 23.1 months
mIFL 141 43.3% 5.9 months 17.6 months
CapeIRI 145 38.6% 5.8 months 18.9 months
FOLFIRI + Bevacizumab 57 57.9% 11.2 months Not yet reached
mIFL + Bevacizumab 60 53.3% 8.3 months 19.2 months
NO16966
FOLFOX/XELOX + Placebo 699 38% OR 1.00
p = 0.99
9.4 months HR 0.83
p = 0.0023
21.3 months HR 0.89
p = 0.0769 FOLFOX/XELOX + Bevacizumab 701 38% 8.0 months 19.9 months
second-Line Phase III 
trials
relevant treatment Arms n response rate Progression-Free 
survival
Overall survival
E3200
FOLFOX4 285 8.6%
p < 0.0001
4.7 months HR 0.61
P <
0.0001
10.8 months HR 0.75
p = 0.001 FOLFOX4 + Bevacizumab 287 22.7% 7.3 months 12.9 months
table 2:  seminal publications supporting the use of bevacizumab in advanced colorectal cancer. Abbreviations: HR, hazards 
ratio; OR, odds ratioOncotarget 2010; 1:  515 - 529 520 www.impactjournals.com/oncotarget
the addition of bevacizumab to FOLFOX improved RR, 
median PFS, and median OS [89]. (Table 2)
The  clinical  efficacy  of  bevacizumab  in  the 
metastatic setting led to the development of two pivotal 
phase III clinical trials in patients with resected stage II 
or III colon cancer.  The NSABP C-08 study failed to 
show an improvement in disease-free or overall survival 
with the addition of bevacizumab to FOLFOX [90].  The 
results of the second trial, AVANT, are anticipated later 
this year (NCT00112918).
Several oral angiogenesis inhibitors are under 
investigation for the treatment of mCRC. (Table 1)  Agents 
which have completed phase III clinical trials include 
valatinib and cediranib.  Valatinib inhibits all known VEGF 
tyrosine kinase receptors.  There have been two phase III 
studies testing this agent in mCRC.  In CONFIRM-1, 
patients  were  assigned  to  receive  first-line  FOLFOX 
+ valatinib or placebo but this study failed to meet its 
primary endpoint of PFS [91].  Similarly, CONFIRM-2, 
which was the second-line study of FOLFOX + valatinib 
or placebo, also did not meet its primary endpoint for 
OS [92].  HORIZON III is a randomized comparison 
of FOLFOX + cediranib (AZ2171), a highly potent and 
selective inhibitor of the three VEGF receptors, and 
FOLFOX + bevacizumab as first-line chemotherapy in 
mCRC.  Although not yet published, a media release in 
March 2010 has confirmed that the study failed to meet its 
primary endpoint of non-inferiority for PFS [93].
PrOMIsING NOVEL ANtIANGIOGENIc 
AGENts FOr GI tUMOrs 
Despite many clinical trials, the only approved 
antiangiogenic therapies in GI tumours are bevacizumab 
and sorafenib, in advanced CRC and HCC, respectively.   
These will be the gold standard that all other agents in 
their class must compete against and no others have yet  table 3.  Ongoing GI clinical trials with selected novel antiangiogenic TKIs.
Nct trial 
Number
Phase tumor 
type
Line of 
therapy
control arm Investigational arm
NCT01046864 I GI, not 
pancreas
N/A N/A 5FU/LV+brivanib; FOLFIRI+brivanib
FOLFIRI+brivanib in Japanese
NCT00825955 III HCC 2
nd BSC+placebo BSC+brivanib
NCT01108705 III HCC 
(asian)
2
nd BSC+placebo BSC+brivanib
NCT00640471 III CRC ≥ 3
rd cetuximab+placebo cetuximab+brivanib
NCT00858871 III HCC 1
st sorafenib+placebo brivanib+placebo
NCT00437424 I HCC with 
liver 
dysfxn
N/A N/A brivanib
NCT00594984 I/II CRC N/A N/A Irinotecan+cetuximab+brivanib
NCT00355238 II HCC ≥ 1
st N/A brivanib
NCT00207051 I Advanced 
GI
N/A N/A cetuximab+brivanib
NCT00707889 II CRC ≥ 2
nd FOLFOX+Bev FOLFOX+high dose ABT-869; FOLFOX+low 
dose ABT-869
NCT00517920 II HCC N/A N/A ABT-869
NCT01009593 III HCC 1
st sorafenib ABT-869
NCT00753675 II biliary 1st gemcitabine+placebo AZD6474+placebo; AZD6474+gemcitabine
NCT00500292 II CRC 2
nd FOLFOX+placebo FOLFOX+low dose AZD6474; FOLFOX+high 
dose AZD6474
NCT00508001 II HCC 1
st BCS+placebo BSC+ low dose AZD6474; 
BSC+high dose AZD6474
NCT00454116 II CRC 2
nd FOLFIRI+placebo FOLFIRI+low dose AZD6474;
FOLFIRI+high dose AZD6474
NCT00436072 I CRC N/A cetuximab+AZD6474; 
irinotecan+cetuximab+AZD6474
NCT00681798 I Pancreas any N/A gemcitabine+capecitabine+AZD6474
NCT00732745 I/II Esophagus
GEJ
Any docetaxel+oxaliplatin docetaxel+oxaliplatin+AZD6474
NCT00499850 I CRC Any N/A FOLFOX+AZD6474
NCT00532909 I CRC any N/A capecitabine+oxaliplatin+cetuximab+AZD6474
NCT00683787 II gastroesop ≤ 2
nd docetaxel docetaxel+low dose AZD6474; 
docetaxel+high dose AZD6474
table 3:  Ongoing clinical trials with anti-VEGF tKIs. Abbreviations: GI, gastrointestinal; HCC, hepatocellular; N/A, not applicable; 
Bev, bevacizumab; CRC, colorectal cancer; GEJ, gastroesophageal junctionOncotarget 2010; 1:  515 - 529 521 www.impactjournals.com/oncotarget
been successful.  Additionally, there are no approved 
indications in gastroesophageal and pancreatic cancers for 
antiangiogenic compounds.  Nonetheless, multiple other 
novel agents are currently under investigation.  Below is 
a summary of the most promising agents that may prove 
beneficial in patients with GI malignancies.
sMALL MOLEcULE tKIs
brivanib alaninate
Brivanib alaninate is an oral small molecule 
TKI active against VEGFR-1, VEGFR-2, VEGFR-3, 
and  fibroblast  growth  factor  (FGF)  receptor  (FGFR).   
The FGF pathway has a demonstrated role in cancer 
progression and FGF level are elevated akin to VEGF 
levels in malignancy [94,95].  Dual blockade of VEGFRs 
and FGFR is attractive clinically as FGF signaling has 
been implicated in resistance to VEGFR inhibition [96].   
There is particular interest in the development of this drug 
in some GI malignancies due to particularly high levels 
of FGF in HCC and the known FGF overexpression in 
gastric cancer [97,98].  Multiple phase I studies have 
demonstrated safety of brivanib both alone and in 
combination with cytotoxics.  Ongoing trials in GI cancers 
are listed in table 3.
Abt-869 
ABT-869 is an oral potent TKI inhibitor of 
VEGFR-1, VEGFR-2, VEGFR-3, PDGFRß, and Flt3 
[99,100].  Data suggests ABT-869 is more selective 
toward VEGFR and PDGFR than other similar TKIs while 
also having apoptotic effects [101].  Efficacy was seen 
with this drug in colorectal xenografts models [101].  A 
phase I dose escalation study recently published reported 
drug tolerability with toxicities including proteinuria, 
hypertension, fatigue, hand-foot blistering, and myalgias 
[99].  Three patients achieved partial response with 
48% of patients recording stable disease.  Effective 
antiangiogenesis was noted on dynamic contrast enhanced 
magnetic resonance imaging (DCE-MRI) which may act 
as a biomarker after further evaluation.  The majority of 
clinical development of this agent is ongoing in CRC 
and HCC.  Interim results from a phase II study in Child-
Pugh A and B HCC reported tolerable toxicities and 42% 
of evaluable patients were progression free at 16 weeks 
[102].  Other ongoing GI trials using ABT-869 are listed 
in table 3.
ZD6474
ZD6474 is a TKI potently inhibiting VEGFR-2, 
Rearranged during Transfection (RET), Flt-4, and EGFR 
[103,104].  Initial  dose  finding  studies  in  patients  with 
advanced solid malignancies who had failed standard of 
care treatments report good tolerability at doses <300mg 
[105,106].  As preclinical data supported use in a wide 
spectrum of human malignancies, clinical development of 
AZ6474 has been across multiple tumor types.  In colon 
cancers, ZD6474 has been combined with FOLFIRI and 
FOLFOX with good tolerability [107,108].  A phase II 
study of FOLFIRI plus ZD6474 did not confirm benefit 
with the combination [109].  A combination of gemcitabine 
+ capecitabine + ZD6474 in biliary and pancreatic cancer 
has shown promising early clinical results [110].  There 
is additional preclinical data supporting ZD6474 use in 
gastric cancers [111,112].  Ongoing clinical trials in GI 
cancers are listed in table 3.
INHIbItING VEGFrs
ramucirumab
table 4: Ongoing clinical trials with anti-VEGFr mAbs. Abbreviations: HCC, hepatocellular; CRC, colorectal; BSC, best supportive 
care; Bev, bevacizu
table 4.  Ongoing clinical trials of anti-VEGFR monoclonal antibodies.
Nct trial 
Number
Phase tumor
type
Line of 
therapy
control arm Investigational arm
NCT01140347 III HCC 2nd BSC ramucirumab
NCT01170663 III gastric 2nd paclitaxel+placebo paclitaxel+ramucirumab
NCT01183780 III CRC 2nd FOLFIRI+placebo FOLFIRI+ramucirumab
NCT01079780 II CRC ≥ 2
nd,
post 
Bev
irinotecan+cetuximab Irinotecan+cetuximab+ramucirumab
NCT01111604 II/III CRC 2nd FOLFOX FOLFOX+ramucirumab; 
FOLFOX+IMC-18F1
NCT00917384 III gastric 2ND placebo+BSC Ramucirumab+BSCOncotarget 2010; 1:  515 - 529 522 www.impactjournals.com/oncotarget
Ramucirumab is a fully human mAb with low pM 
affinity to the VEGF-binding domain of VEGFR-2 [113].   
Dose-finding studies were undertaken with weekly and 
every 2 and 3 week single agent administration with very 
good drug tolerance [114,115].  Common toxicities were 
as expected based on the antibodies’ mechanism of action 
and included thrombotic events, hypertension, proteinuria, 
and bleeding.  Initial reports suggest a greater clinical 
benefit with the use of ramucirumab than other clinically 
tested antiangiogenic agents, though randomized clinical 
trials must be undertaken to prove superiority [114,116].   
More advanced studies using a dose of 8 mg/kg every 2 
weeks are ongoing and listed in table 4.  Early data from 
the phase II study of ramucirumab used in the first-line 
setting in Childs-Pugh A and B HCC is promising in 
sorafenib-naïve patients with a 50% disease control rate 
[117].
IMc-18F1
IMC-18F1 has had a slower clinical development 
compared to ramucirumab.  An intravenous recombinant 
human IgG1 anti-VEGFR-1 mAb, IMC-18F1 inhibits 
ligand-induced VEGFR-1 activation at low pM 
concentrations [118].  Final data from a multi-schedule 
phase I single agent dose finding study is pending but 
preliminary information revealed safely and biologic 
activity supporting further development of the drug [119]. 
Clinical development of IMC-18F1 is listed in table 4.
Decoy fusion proteins
Aflibercept,  a  novel  fully  human  recombinant 
decoy fusion protein, has recently completed phase I 
clinical testing [120,121].  Mimicking immunoglobin 
domains of VEGFR-1 and VEGFR-2, it has low pM 
affinity for VEGF, VEGF-B and PlGF [122,123].  When 
administered  intravenously  every  2  weeks,  aflibercept 
was well tolerated with rectal ulceration and proteinuria 
being the dose limiting toxicities.  Other toxicities were 
in keeping with inhibition of the VEGF/VEGFR pathway.   
Three patients experienced a partial response.  A phase 
II study in metastatic CRC has also demonstrated benefit 
in a bevacizumab pre-treated cohort prompting further 
investigations in this area [124].  Ongoing studies with 
aflibercept in GI malignancies are listed in table 5. 
sUMMArY 
Antiangiogenic agents have clearly advanced the 
treatment of GI malignancies, most notably CRC and 
HCC. Unfortunately, there have been no advances in 
the treatment of incurable EGC and pancreas cancer 
using antiangiogenic agents and prognosis remains poor.   
Despite the promising results in CRC with bevacizumab 
and HCC with sorafenib, multiple clinical trials using 
other methods of blocking the VEGF pathway have 
been negative in these and the other GI malignancies.   
The mechanisms of resistance to VEGF inhibition is not 
known.  Despite preclinical models suggesting that VEGF 
inhibition should be effective in all GI malignancies; this 
has not been confirmed in clinical practice.
Uncertainty exists in many of these negative trials 
as to why the study or drug failed.  Likely, the answer 
is multifactorial being related to a combination of drug 
ineffectiveness once used in a randomized phase III setting, 
poor clinical trial design, suboptimal patient selection, 
and lack of a reliable biomarker to direct clinicians on 
which patients will or will not benefit.   The importance 
of predictors for treatment response of these agents are 
exemplified well by the results of the AVAGAST study 
table 5.  Ongoing clinical trials with aflibercept.
Nct trial 
Number
Phase tumor 
type
Line of 
therapy
control 
arm
Investigational arm
NCT00574275 III pancreatic  2
nd placebo aflibercept
NCT00561470 III advanced 
CRC
2
nd irinotecan 
+ 5FU
irinotecan+5FU+aflibercept
NCT00851084 II advanced 
CRC
1
st FOLFOX FOLFOX+aflibercept
NCT00407654 II advanced 
CRC
± 2
nd N/A aflibercept
NCT00921661 I advanced 
CRC in 
Japanese
N/A N/A FOLFIRI+aflibercept
Table 5: Ongoing clinical trials with aflibercept. Abbreviations: CRC, colorectal cancer; 5FU, %-fluorouracil; N/A, not applicableOncotarget 2010; 1:  515 - 529 523 www.impactjournals.com/oncotarget
suggesting that there is a patient population which may 
benefit from the addition of an angiogenesis inhibitor, but 
when studied in a general patient population, a survival 
benefit could not be attained. Biomarkers are needed to 
delineate those patients who will benefit and those who 
will not.
In CRC, investigations are underway to determine 
genetic  profiles  or  other  patient  characteristics  to  help 
identify  those  who  will  benefit  from  anti-angiogenic 
inhibition.  Until trials can clarify the optimal use of 
these agents, data supports exposure, at some point in the 
treatment of mCRC, to bevacizumab in fit patients.  In all 
GI tumors, the use of newer genetically engineered cancer 
models may help elucidate mechanisms of resistance 
or biomarkers to aid clinician treatment choices [125].   
Additionally, though not necessarily practical, the use of 
newer imaging techniques, like DCE-MRI, may play a 
role in early determination of antiangiogenic efficacy.
Until the time when biomarkers are identified and 
validated to predict effectiveness of these agents, we 
may be wasting precious resources in trying to develop 
antiangiogenic agents further.  New agents look attractive 
but intelligent clinical trial development will be required 
to find these new drugs a niche in an already saturated area 
of cancer treatment.
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